公开(公告)号：WO2011079105A1

公开(公告)日：2011-06-30

申请号：PCT/US2010/061475

申请日：2010-12-21

Applicant: ABBOTT LABORATORIES ,  ERICSSON, Anna M. ,  EDMUNDS, Jeremy J. ,  HOBSON, Adrian D. ,  STEWART, Kent D. ,  WISHART, Neil ,  WANG, Lei ,  IHLE, David C. ,  FERENZ, Catherine R. ,  DUNSTAN, Theresa A. ,  WANG, Lu

Inventor： ERICSSON, Anna M. ,  EDMUNDS, Jeremy J. ,  HOBSON, Adrian D. ,  STEWART, Kent D. ,  WISHART, Neil ,  WANG, Lei ,  IHLE, David C. ,  FERENZ, Catherine R. ,  DUNSTAN, Theresa A. ,  WANG, Lu

IPC: C07D265/00

CPC classification number: C07D487/04 ,  C07D487/08 ,  C07D495/04 ,  C07D498/04

Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供式（I）化合物的药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：WO2009039135A1

公开(公告)日：2009-03-26

申请号：PCT/US2008/076594

申请日：2008-09-17

Applicant: ABBOTT LABORATORIES ,  DONNER, Pamela L. ,  RANDOLPH, John T. ,  KRUEGER, Allan C. ,  BETEBENNER, David A. ,  HUTCHINSON, Douglas K. ,  LIU, Dachun ,  LIU, Yaya ,  LONGENECKER, Kenton L. ,  MARING, Clarence J. ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  ZHANG, Geoff G. Z.

Inventor： DONNER, Pamela L. ,  RANDOLPH, John T. ,  KRUEGER, Allan C. ,  BETEBENNER, David A. ,  HUTCHINSON, Douglas K. ,  LIU, Dachun ,  LIU, Yaya ,  LONGENECKER, Kenton L. ,  MARING, Clarence J. ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  ZHANG, Geoff G. Z.

IPC: C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D239/553 ,  A61K31/513 ,  A61K31/506 ,  A61P31/14

CPC classification number: C07D239/22 ,  A61K31/513 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)

Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。 该化合物在丙型肝炎的治疗中是有用的，具有以下通用结构：式（I）

公开(公告)号：WO2011068899A1

公开(公告)日：2011-06-09

申请号：PCT/US2010/058598

申请日：2010-12-01

Applicant: ABBOTT LABORATORIES ,  WISHART, Neil ,  ARGIRIADI, Maria A. ,  BREINLINGER, Eric C. ,  CALDERWOOD, David J. ,  ERICSSON, Anna M. ,  FIAMENGO, Bryan A. ,  FRANK, Kristine E. ,  FRIEDMAN, Michael ,  GEORGE, Dawn M. ,  GOEDKEN, Eric R. ,  JOSEPHSOHN, Nathan S. ,  LI, Biqin C. ,  MORYTKO, Michael J. ,  MULLEN, Kelly D. ,  SOMAL, Gagandeep ,  STEWART, Kent D. ,  VOSS, Jeffrey W. ,  WALLACE, Grier A. ,  WANG, Lu ,  WOLLER, Kevin R.

Inventor： WISHART, Neil ,  ARGIRIADI, Maria A. ,  BREINLINGER, Eric C. ,  CALDERWOOD, David J. ,  ERICSSON, Anna M. ,  FIAMENGO, Bryan A. ,  FRANK, Kristine E. ,  FRIEDMAN, Michael ,  GEORGE, Dawn M. ,  GOEDKEN, Eric R. ,  JOSEPHSOHN, Nathan S. ,  LI, Biqin C. ,  MORYTKO, Michael J. ,  MULLEN, Kelly D. ,  SOMAL, Gagandeep ,  STEWART, Kent D. ,  VOSS, Jeffrey W. ,  WALLACE, Grier A. ,  WANG, Lu ,  WOLLER, Kevin R.

IPC: A01N43/42 ,  A61K31/44

CPC classification number: C07F9/06 ,  C07D471/14 ,  C07D487/14 ,  C07D498/14 ,  C07D513/14

Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供了式（Ia），（Ib），（Ic），（Id），（Ie），（If），（Ig），（Ih），（Ii），（Ij），（Ik） ，或（II），其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：WO2010111437A1

公开(公告)日：2010-09-30

申请号：PCT/US2010/028561

申请日：2010-03-25

Applicant: ABBOTT LABORATORIES ,  ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf

Inventor： ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf

IPC: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14 ,  A61K31/513 ,  A61P31/12

CPC classification number: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备此类中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：WO2009039127A1

公开(公告)日：2009-03-26

申请号：PCT/US2008/076576

申请日：2008-09-17

Applicant: ABBOTT LABORATORIES ,  WAGNER, Rolf ,  TUFANO, Michael D. ,  STEWART, Kent D. ,  ROCKWAY, Todd W. ,  RANDOLPH, John T. ,  PRATT, John K. ,  MOTTER, Christopher E. ,  MARING, Clarence J. ,  LONGENECKER, Kenton L. ,  LIU, Yaya ,  LIU, Dachun ,  KRUEGER, Allan C. ,  KATI, Warren M. ,  HUTCHINSON, Douglas K. ,  HUANG, Peggy P. ,  FLENTGE, Charles A. ,  DONNER, Pamela L. ,  DEGOEY, David A. ,  BETEBENNER, David A. ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  SARRIS, Kathy ,  ZHANG, Geoff G. Z.

Inventor： WAGNER, Rolf ,  TUFANO, Michael D. ,  STEWART, Kent D. ,  ROCKWAY, Todd W. ,  RANDOLPH, John T. ,  PRATT, John K. ,  MOTTER, Christopher E. ,  MARING, Clarence J. ,  LONGENECKER, Kenton L. ,  LIU, Yaya ,  LIU, Dachun ,  KRUEGER, Allan C. ,  KATI, Warren M. ,  HUTCHINSON, Douglas K. ,  HUANG, Peggy P. ,  FLENTGE, Charles A. ,  DONNER, Pamela L. ,  DEGOEY, David A. ,  BETEBENNER, David A. ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  SARRIS, Kathy ,  ZHANG, Geoff G. Z.

IPC: C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61P31/12 ,  A61K31/513

CPC classification number: A61K31/513 ,  A61K31/5377 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

Abstract: Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

Abstract translation: 本申请涉及可用于治疗丙型肝炎（HCV）感染的式I化合物。 所公开的化合物的结构是通过亚苯基连接成稠合的2-环环系（R6）或者另外通过另外的两个原子连接基（L）与5-6元单环（R6）连接的尿嘧啶或胸腺嘧啶衍生物。 应用进一步公开了两种特定化合物的多晶型物和假多晶型物：N-（6（3-叔丁基-5-（2,4-二氧代-3,4-二氢嘧啶-1（2H） - 基）-2-甲氧基 - 苯基 ）萘-2-基）甲磺酰胺和（E）-N-（4（3-叔丁基-5-（2,4-二氧代-3）4-二氢嘧啶-1（2H） - 基）2-甲氧基 - 苯乙烯基 - 苯基）甲磺酰胺。

公开(公告)号：EP2421845A1

公开(公告)日：2012-02-29

申请号：EP10712220.2

申请日：2010-03-25

Applicant: Abbott Laboratories

Inventor： ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  MARING, Clarence, J.

IPC: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14 ,  A61K31/513 ,  A61P31/12

CPC classification number: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

公开(公告)号：EP1358154A2

公开(公告)日：2003-11-05

申请号：EP00972042.6

申请日：2000-10-10

Applicant: Abbott Laboratories

Inventor： MARING, Clarence J. ,  GIRANDA, Vincent L. ,  KEMPF, Dale J. ,  STOLL, Vincent S. ,  SUN, Minghua ,  ZHAO, Chen ,  GU, Yu Gui ,  HANESSIAN, Stephen ,  WANG, Gary T. ,  KRUEGER, Allan C. ,  CHEN, Hui-Ju ,  CHEN, Yuanwei ,  DEGOEY, David A. ,  FLOSI, William J. ,  GRAMPOVNIK, David J. ,  KATI, Warren M. ,  KENNEDY, April L. ,  KLEIN, Larry L. ,  LIN, Zhen ,  MADIGAN, Darold L. ,  MCDANIEL, Keith F. ,  MUCHMORE, Steven W. ,  SHAM, Hing L. ,  STEWART, Kent D. ,  TU, Noah P. ,  WAGENAAR, Frank L. ,  WANG, Sheldon ,  WIEDEMAN, Paul E. ,  XU, Yibo ,  YEUNG, Ming C. ,  BAYRAKDARIAN, Malken ,  LUO, Xuehong

IPC: C07D207/16 ,  C07D403/04 ,  C07D417/04

CPC classification number: C07D207/16 ,  C07D207/26 ,  C07D207/327 ,  C07D207/38 ,  C07D207/46 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D303/16 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D413/04 ,  C07D417/04 ,  C07D417/06

Abstract: Enantiomerically enriched compounds having the absolute stereochemistry of the formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

公开(公告)号：EP2421845B1

公开(公告)日：2013-04-17

申请号：EP10712220.2

申请日：2010-03-25

Applicant: Abbott Laboratories

Inventor： ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  MARING, Clarence, J.

IPC: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14 ,  A61K31/513 ,  A61P31/12

CPC classification number: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14

公开(公告)号：EP2091943A2

公开(公告)日：2009-08-26

申请号：EP07821595.1

申请日：2007-10-19

Applicant: Abbott GmbH & Co. KG ,  ABBOTT LABORATORIES

Inventor： TURNER, Sean Colm ,  BAKKER, Margaretha Henrica Maria ,  STEWART, Kent D.

IPC: C07D401/12 ,  C07D413/14 ,  C07D471/04 ,  A61K31/4709 ,  A61K31/497 ,  A61P25/00

CPC classification number: C07D401/12 ,  C07D241/20 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention relates to a heterocyclic compound of the general formula (I) and their use and preparation, methods of making the compounds, compositions containing at least one of said compounds, and methods of treatment using at least one compound. In particular, compounds of the general formula (I) are useful for inhibiting glycogen synthase kinase 3 (GSK-3),

公开(公告)号：EP2203430B1

公开(公告)日：2011-06-15

申请号：EP08831558.5

申请日：2008-09-17

Applicant: Abbott Laboratories

Inventor： DONNER, Pamela L. ,  RANDOLPH, John T. ,  KRUEGER, Allan C. ,  BETEBENNER, David A. ,  HUTCHINSON, Douglas K. ,  LIU, Dachun ,  LIU, Yaya ,  LONGENECKER, Kenton L. ,  MARING, Clarence J. ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  ZHANG, Geoff G. Z.

IPC: C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D239/553 ,  A61K31/513 ,  A61K31/506 ,  A61P31/14

CPC classification number: C07D239/22 ,  A61K31/513 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)